In February 2018, baloxavirmarboxil (trade name: xofluza), a new anti influenza drug developed by Shionogi of Japan and jointly studied with Roche of Switzerland, was accelerated in Japan and approved for listing. Baloxavir axetil is an innovative cap dependent endonuclease inhibitor. It is also one of the few new drugs in the world that can inhibit the proliferation of influenza virus.
Audited Supplier 
){kind=link}